Thursday, 24 Aug 2017

TNF inhibitor

Datesort ascending Type Title Save
31 Mar 2016 Social Retrospective, comparative efficacy ADA,ETN,INF in 307 RA shows equal safety & efficacy; remissions 7.4/100PY/month https://t.co/FgrQqQsB49
30 Mar 2016 Social @RonanTKavanagh Fear of unknown is reason to ask for help (didnt happen). Stopping biologics will results in flare. Inflamm +XRT = bad news
24 Mar 2016 News First Head-to-Head TNF Trial Ends in a Draw
24 Mar 2016 Social 1st TNFi H2H results are in: EXXELERATE study Cimzia vs Humira shows equal ACR20 @3mo (69 v 71%) & LDAS @2y(35 v 33) https://t.co/qvcQdnAlxy
23 Mar 2016 Social Real life H2H comparison 295 Humira & 84 Infliximab Rx Crohns showed non-significant equal failure rates (21 vs 25%) https://t.co/okUyyCE4nL
17 Mar 2016 Social Anti-Remicade Abs 100% cross reactive w/ its biosimilar CT-P13 (Remsima/Inflectra) as further proof of biosimilarity https://t.co/8i6aUhrFdZ
17 Mar 2016 News TNF Inhibitors Increase Perioperative Infection Risk
03 Mar 2016 Social History of breast cancer pts can safely get TNF inhibitors without added risk of recurrence (from the TNFi) - data, guidelines support this
02 Mar 2016 News TNF Inhibition and Heart Failure
01 Mar 2016 Social Prior hx of Cancer in IBD patients does not preclude the use of TNF inhibitors. https://t.co/D58N3Jj2cQ
29 Feb 2016 Slide of the day How to manage TNFi during surgery
22 Feb 2016 Social Emery & colleagues plan to study rapidity/depth of remission of VERY early Enbrel (@1st visit) in early RA (VEDERA) https://t.co/UsoUlt9PoH
16 Feb 2016 Social Infliximab induced skin manifestations (23%) includes eczema and psoriasis like lesions - 41% were exacerbations https://t.co/8V9T2tyIL4
13 Feb 2016 Social FDA arthritis advisory votes 21-3 in favor of approving the Celltrion CT-P13 (Inflectra) a biosimilar of infliximab https://t.co/P6R75QOB7j
09 Feb 2016 News FDA Advisory Arthritis Committee Votes to Approve the CT-P13 (infliximab) Biosimilar
09 Feb 2016 News FDA Reviews Celltrion's Remicade Biosimilar Today
26 Jan 2016 News Risk of Multiple Sclerosis with TNF Inhibitor Therapy
07 Dec 2015 Social RA on TNFi: 53% nonadherent, 20% markedly so. Nonadherence assoc w/ Low dz activity, comorbidity, age, MD-Pt discord https://t.co/ixsMCYad8R
07 Dec 2015 Social Amgen filed its application for ABP-501 (Humira biosimilar) for approval w/ the EMA; includes Pso, RA, switch data https://t.co/Rfr6Z3XYQt
04 Dec 2015 News In RA TNF-Inhibitors Prove To Be Durable Choice